Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 6:ciac454. doi: 10.1093/cid/ciac454

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 4. — Effectiveness of 3 doses of BNT162b2 vaccine over time since vaccination during a period dominated by Omicron (20 December 2021 to 5 April 2022) relative to findings in (1) unvaccinated employees and (2) employees who had received 2 doses of BNT162b2 <6 months before testing. Estimates were adjusted for age, sex, race/ethnicity, presence of symptoms, work role (clinical or nonclinical), rolling average case rates per 100 000 people on the specimen collection date for the employee’s county of residence, and the specimen collection week.